Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
45 hedge funds and large institutions have $435M invested in Centessa Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 4 closing their positions.
114% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 7
69% more capital invested
Capital invested by funds: $258M → $435M (+$178M)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3.12% more ownership
Funds ownership: 70.44% → 73.57% (+3.1%)
2% more funds holding
Funds holding: 44 → 45 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
79% less call options, than puts
Call options by funds: $7K | Put options by funds: $33K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$10.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.38M |
| 3 |
SCM
Sio Capital Management
New York
|
+$2.51M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.12M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
+$1.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$6.52M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$229K |
| 3 |
TWM
Tanager Wealth Management
Goring On Thames,
United Kingdom
|
-$194K |
| 4 |
JP Morgan Chase
New York
|
-$189K |
| 5 |
Jane Street
New York
|
-$155K |
CNTA Hedge Fund Activity: Q2 2023 in Review
45 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q2 2023, worth a combined $435M — up 69% from $258M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CNTA positions and 4 closed out — a net gain of 1 holder — while 15 added to existing stakes and 7 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $10.7M. The largest seller was Samsara BioCapital, exiting entirely with an estimated $6.52M sold.
- 45 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q2 2023, up from 44 in Q1 2023.
- Funds reported $435M of Centessa Pharmaceuticals stock for Q2 2023, up 69% quarter-over-quarter.
- 5 funds opened new Centessa Pharmaceuticals positions in Q2 2023 and 4 closed out, a net change of +1 holder.
- The largest Centessa Pharmaceuticals buyer in Q2 2023 was Adage Capital Partners, an estimated $10.7M added.
- The largest Centessa Pharmaceuticals seller in Q2 2023 was Samsara BioCapital, an estimated $6.52M sold.
Based on aggregated 13F filings for Q2 2023.